miltefosine and Leishmania Infection studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Research Excerpts

Excerpt	Relevance	Reference
"Miltefosine is a new oral treatment against leishmaniasis."	8.88	Miltefosine and cutaneous leishmaniasis. ( Machado, PR; Penna, G, 2012)
" Since 1998 Indian researchers have conducted clinical trials evaluating hexadecylphosphocoline (miltefosine) in patients with visceral leishmaniasis and in 1999 clinical studies were initiated in Colombia in patients with cutaneous leishmaniasis."	8.83	[Oral miltefosine to treat leishmaniasis]. ( Soto, J; Soto, P, 2006)
" Beginning in 1998, Indian researchers conducted several trials with hexadecylphosphocholine (miltefosine) in patients with visceral leishmaniasis, and in 1999, clinical studies were initiated in Colombia for cutaneous disease."	8.83	Miltefosine: oral treatment of leishmaniasis. ( Soto, J; Soto, P, 2006)
"Miltefosine is an important drug for the treatment of leishmaniasis; however, its mechanism of action is still poorly understood."	7.88	Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections. ( Huyghues Despointes, CE; Kima, PE; Prasad, S; Young, J; Zhang, N, 2018)
" The compounds were evaluated for their in vivo antimalarial activity against Plasmodium berghei infected mice and the most active derivatives were further examined for their in vitro antimalarial activity against chloroquine resistant (RKL9) strain of Plasmodium falciparum."	7.81	New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents. ( Abd El Razik, HA; Bekhit, AA; Bekhit, Ael-D; El-Agroudy, EJ; El-Miligy, MM; Hassan, AM, 2015)
"Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed."	7.72	Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. ( Bommer, W; Engel, KR; Fischer, C; Sindermann, H, 2004)
"Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year."	6.52	Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. ( Fujinami, N; Shah, PJ; Vakil, NH, 2015)
"Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi."	6.48	Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. ( Balasegaram, M; Beijnen, JH; de Vries, PJ; Dorlo, TP, 2012)
"Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers."	6.43	Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006)
"Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas."	5.36	Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010)
"Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models."	5.32	Miltefosine (Impavido): the first oral treatment against leishmaniasis. ( Bommer, W; Croft, SL; Eibl, HJ; Engel, J; Engel, KR; Sindermann, H; Unger, C, 2004)
"Miltefosine is a new oral treatment against leishmaniasis."	4.88	Miltefosine and cutaneous leishmaniasis. ( Machado, PR; Penna, G, 2012)
" Beginning in 1998, Indian researchers conducted several trials with hexadecylphosphocholine (miltefosine) in patients with visceral leishmaniasis, and in 1999, clinical studies were initiated in Colombia for cutaneous disease."	4.83	Miltefosine: oral treatment of leishmaniasis. ( Soto, J; Soto, P, 2006)
"Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions."	4.83	Miltefosine: issues to be addressed in the future. ( Berman, J; Bryceson, AD; Croft, S; Engel, J; Gutteridge, W; Karbwang, J; Sindermann, H; Soto, J; Sundar, S; Urbina, JA, 2006)
"Although three new drugs or drug formulations, liposomal amphotericin B (AmBisome), miltefosine and paromomycin should be available for the treatment of visceral leishmaniasis (VL) within the next year, they all suffer from limitations of either cost, specific toxicities or parenteral administration."	4.83	Current scenario of drug development for leishmaniasis. ( Croft, SL; Seifert, K; Yardley, V, 2006)
" Since 1998 Indian researchers have conducted clinical trials evaluating hexadecylphosphocoline (miltefosine) in patients with visceral leishmaniasis and in 1999 clinical studies were initiated in Colombia in patients with cutaneous leishmaniasis."	4.83	[Oral miltefosine to treat leishmaniasis]. ( Soto, J; Soto, P, 2006)
"In this review we have summarized published data on two new compounds, which can represent important antiparasitic drugs in the near future, nitazoxanide for treatment of intestinal parasitic infections including cryptosporidiosis and miltefosine for oral treatment of visceral leishmaniasis."	4.82	[New drugs for treatment of parasitic infections]. ( Lobovská, A; Nohýnková, E, 2003)
"The obtained results indicated that dineolignans 1 and 2 could be considered as a scaffold for the design of novel and selective drug candidates for the treatment of leishmaniasis."	3.91	Antileishmanial activity and ultrastructural changes of related tetrahydrofuran dineolignans isolated from Saururus cernuus L. (Saururaceae). ( Barbosa, H; Bezerra-Souza, A; Brito, JR; Ferreira, EA; Lago, JHG; Laurenti, MD; Passero, LFD; Romoff, P, 2019)
"Increasing drug resistance towards first line antimony-derived compounds has forced the introduction of novel therapies in leishmaniasis endemic areas including amphotericin B and miltefosine."	3.88	High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms. ( Bresson, E; Fernandez-Prada, C; Leprohon, P; Ouellette, M; Plourde, M; Roy, G; Sharma, M, 2018)
"Miltefosine is an important drug for the treatment of leishmaniasis; however, its mechanism of action is still poorly understood."	3.88	Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections. ( Huyghues Despointes, CE; Kima, PE; Prasad, S; Young, J; Zhang, N, 2018)
" In this study, we explored the role of human macrophage transporters in the intracellular accumulation and antileishmanial activity of miltefosine (MLF), the only oral drug available for the treatment of visceral and cutaneous leishmaniasis (CL)."	3.83	Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS. ( Dohmen, LC; Dorlo, TP; Gomez, MA; Gregory, DJ; Kip, A; Navas, A; Vargas, DA, 2016)
"Leishmaniasis, a fatal parasitic disease, is the second largest parasitic killer in the world and miltefosine is the first and only oral drug available for its treatment."	3.83	LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma. ( Jaiswal, S; Lal, J; Sharma, A; Shukla, M, 2016)
"Miltefosine is the first oral drug used in chemotherapy against leishmaniasis."	3.83	Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance. ( Laffitte, MC; Légaré, D; Leprohon, P; Ouellette, M, 2016)
" The compounds were evaluated for their in vivo antimalarial activity against Plasmodium berghei infected mice and the most active derivatives were further examined for their in vitro antimalarial activity against chloroquine resistant (RKL9) strain of Plasmodium falciparum."	3.81	New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents. ( Abd El Razik, HA; Bekhit, AA; Bekhit, Ael-D; El-Agroudy, EJ; El-Miligy, MM; Hassan, AM, 2015)
"As part of Drugs for Neglected Diseases initiative's lead optimization program for the development of new chemical entities to treat visceral leishmaniasis (VL), a series of aminothiazoles were synthesized and screened for in vitro efficacy, solubility and microsomal stability."	3.81	Aminothiazoles: Hit to lead development to identify antileishmanial agents. ( Bhuniya, D; Dere, RT; Deshpande, A; Gopinath, VS; Gupta, S; Launay, D; Martin, D; Moger, M; Mukkavilli, R; Pati, H; Pradhan, A; Puri, SK; Shivahare, R; Verma, A; Vishwakarma, P, 2015)
"To achieve an integrated assessment of current and innovative therapeutic strategies, we determined host and parasite responses to miltefosine and meglumine antimoniate alone and in combination with pentoxifylline or CpG 2006 in peripheral blood mononuclear cells (PBMCs) of cutaneous leishmaniasis patients."	3.81	Ex vivo host and parasite response to antileishmanial drugs and immunomodulators. ( Fernández, OL; Gonzalez-Fajardo, L; McMahon-Pratt, D; Saravia, NG, 2015)
" In this study, a new semi-synthetic berberine analogue, 5,6-didehydro-8,8-diethyl-13-oxodihydroberberine chloride (1), showed nanomolar level potency against in vitro models of leishmaniasis, malaria, and trypanosomiasis as well as activity in an in vivo visceral leishmaniasis model."	3.77	Potent antiprotozoal activity of a novel semi-synthetic berberine derivative. ( Anklin, C; Bahar, M; Deng, Y; Doskotch, RW; Drew, ME; Gil, RR; He, S; Kinghorn, AD; Navarro-Vázquez, A; Pandharkar, T; Werbovetz, KA; Zhu, X, 2011)
"Although oral miltefosine represented an important therapeutic advance in the treatment of leishmaniasis, the appearance of resistance remains a serious threat."	3.77	Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania. ( Bavchvarov, BI; Campillo, M; Castanys, S; Gamarro, F; López-Martín, C; Martínez-García, M; Pérez-Victoria, JM; Torrecillas, IR, 2011)
"This study aimed to investigate the activity of a combination of topical paromomycin gel and oral miltefosine for the treatment of experimental cutaneous leishmaniasis caused by Leishmania (Leishmania) amazonensis."	3.76	Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. ( Aguiar, MG; Fernandes, AP; Ferreira, LA; Pereira, AM, 2010)
" Once treatment for leishmaniasis was started with miltefosine, CD4+ cell count rose above 400/microL."	3.74	Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients. ( Bestetti, A; Bossolasco, S; Cernuschi, M; Cinque, P; De Bona, A; Gaiera, G; Gianotti, N; Lazzarin, A; Maillard, M, 2008)
"The alkylphosphocholine class of drugs, including edelfosine and miltefosine, has recently shown promise in the treatment of protozoal and fungal diseases, most notably, leishmaniasis."	3.72	Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. ( Birchmore, JL; Hanson, PK; Malone, L; Nichols, JW, 2003)
"Oral miltefosine was administered to 39 human immunodeficiency virus (HIV)-infected patients with leishmaniasis for whom standard leishmaniasis treatment had failed."	3.72	Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. ( Bommer, W; Engel, KR; Fischer, C; Sindermann, H, 2004)
"Leishmaniasis is a parasitic neglected tropical disease caused by various species of Leishmania parasite."	2.72	Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships. ( Bhatia, R; Gupta, O; Monga, V; Pradhan, T, 2021)
"Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year."	2.52	Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. ( Fujinami, N; Shah, PJ; Vakil, NH, 2015)
"Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi."	2.48	Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. ( Balasegaram, M; Beijnen, JH; de Vries, PJ; Dorlo, TP, 2012)
"Amiodarone is also capable to inhibit the oxidosqualene cyclase, a key enzyme in the synthesis of ergosterol."	2.47	Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. ( Benaim, B; Garcia, CR, 2011)
"Leishmaniasis is a parasitic disease caused by hemoflagellate, Leishmania spp."	2.44	Chemotherapy of leishmaniasis: past, present and future. ( Mishra, J; Saxena, A; Singh, S, 2007)
"Oral fluconazole has been shown to be more effective than placebo in one instance: for Leishmania major cutaneous disease from Saudi Arabia."	2.43	Clinical status of agents being developed for leishmaniasis. ( Berman, J, 2005)
"Miltefosine was originally formulated and registered as a topical treatment for cutaneous cancers."	2.43	Development of miltefosine as an oral treatment for leishmaniasis. ( Engel, J; Sindermann, H, 2006)
"Fluconazole treatment for 6 weeks speeds up the already-rapid cure rate of cutaneous disease due to Leishmania major."	2.42	Current treatment approaches to leishmaniasis. ( Berman, J, 2003)
"Leishmaniasis is a parasitic disease caused by a hemoflagellate, Leishmania spp."	2.42	Challenges and new discoveries in the treatment of leishmaniasis. ( Singh, S; Sivakumar, R, 2004)
"Laryngeal leishmaniasis is an unusual form of the disease."	1.62	Case Report: Progressive Dysphonia and Dysphagia due to Laryngeal Leishmaniasis. ( Bakhos, D; Desoubeaux, G; Lemaignen, A; Renard, L, 2021)
"According to WHO, leishmaniasis is a major tropical disease, ranking second after malaria."	1.46	Anti-leishmanial and cytotoxic activities of amino acid-triazole hybrids: Synthesis, biological evaluation, molecular docking and in silico physico-chemical properties. ( Abid, M; Ahmad, MB; Azam, A; Daniliuc, CG; Hasan, P; Masood, MM; Rub, A; Sonawane, YA; Tabrez, S; Yadava, U, 2017)
"Leishmaniasis is a group of tropical diseases caused by protozoan parasites of the genus Leishmania."	1.46	Biochemical and inhibition studies of glutamine synthetase from Leishmania donovani. ( Babu, NK; Kumar, R; Kumar, V; Singh, S; Soumya, N; Yadav, S, 2017)
"His dysphonia was initially managed as bronchiectasis with little improvement."	1.43	Laryngeal leishmaniasis in a patient taking inhaled corticosteroids. ( Mukherjee, J; Phillips, D; Roberts, RM, 2016)
"Miltefosine was used as a control in selection experiments and both stepwise selection and chemical mutagenesis allowed successful isolation of miltefosine resistant mutants."	1.42	Leishmania is not prone to develop resistance to tamoxifen. ( Coelho, AC; Senra, L; Trinconi, CT; Uliana, SR; Yokoyama-Yasunaka, JK, 2015)
"Ocular leishmaniasis is a potentially blinding disease and delay in diagnosis and treatment can cause irreversible damage to the eye and adnexae."	1.42	Caruncular Leishmaniasis--An Unusual Case. ( Badri Prasad, B; Poonam, L; Shakya, A; Smriti, K, 2015)
"Oral treatment with miltefosine is generally well tolerated and has relatively few adverse effects."	1.40	Repurposing miltefosine for the treatment of immune-mediated disease? ( Hommes, DW; Peppelenbosch, MP; van den Brink, GR; Verhaar, AP; Wildenberg, ME, 2014)
"Visceral leishmaniasis is an opportunistic infection that affects human immunodeficiency virus-infected persons in leishmaniasis-endemic areas."	1.36	Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. ( Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D, 2010)
"2%) presented product-related adverse events concerning the gastrointestinal tract."	1.35	Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. ( Bianciardi, P; Mateo, M; Maynard, L; Miró, G; Vischer, C, 2009)
"Leishmaniasis is a protozoan vector borne disease prevalent throughout the world and present in at least 88 countries."	1.35	Development of new antileishmanial drugs--current knowledge and future prospects. ( Le Pape, P, 2008)
"Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models."	1.32	Miltefosine (Impavido): the first oral treatment against leishmaniasis. ( Bommer, W; Croft, SL; Eibl, HJ; Engel, J; Engel, KR; Sindermann, H; Unger, C, 2004)

Research

Studies (94)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Complete Clinical Response

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	27 (28.72)	29.6817
2010's	55 (58.51)	24.3611
2020's	12 (12.77)	2.80

Authors	Studies
Suryawanshi, SN	5
Pandey, S	2
Bhatt, BA	1
Gupta, S	6
Goyal, N	1
Boiani, M	1
Boiani, L	1
Merlino, A	1
Hernández, P	1
Chidichimo, A	1
Cazzulo, JJ	1
Cerecetto, H	1
González, M	1
da Luz, RI	2
Vermeersch, M	2
Dujardin, JC	4
Cos, P	3
Maes, L	4
Esteves, MA	1
Fragiadaki, I	1
Lopes, R	1
Scoulica, E	1
Cruz, ME	1
Singh, IP	1
Jain, SK	1
Kaur, A	1
Singh, S	4
Kumar, R	2
Garg, P	1
Sharma, SS	1
Arora, SK	2
Bahar, M	1
Deng, Y	1
Zhu, X	1
He, S	1
Pandharkar, T	1
Drew, ME	1
Navarro-Vázquez, A	1
Anklin, C	1
Gil, RR	1
Doskotch, RW	1
Werbovetz, KA	1
Kinghorn, AD	1
Kumar, S	3
Tiwari, A	3
Mittal, M	2
Vishwakarma, P	3
Adam, R	1
Bilbao-Ramos, P	1
López-Molina, S	1
Abarca, B	1
Ballesteros, R	1
González-Rosende, ME	1
Dea-Ayuela, MA	1
Alzuet-Piña, G	1
Shivahare, R	2
Kant, P	1
Bekhit, AA	1
Hassan, AM	1
Abd El Razik, HA	1
El-Miligy, MM	1
El-Agroudy, EJ	1
Bekhit, Ael-D	1
Guo, S	1
Wang, J	1
Zhang, X	1
Cojean, S	3
Loiseau, PM	3
Fan, X	1
Bhuniya, D	1
Mukkavilli, R	1
Launay, D	1
Dere, RT	1
Deshpande, A	1
Verma, A	1
Moger, M	1
Pradhan, A	1
Pati, H	1
Gopinath, VS	1
Puri, SK	1
Martin, D	1
Masood, MM	1
Hasan, P	1
Tabrez, S	1
Ahmad, MB	1
Yadava, U	1
Daniliuc, CG	1
Sonawane, YA	1
Azam, A	1
Rub, A	1
Abid, M	1
Ortalli, M	1
Varani, S	1
Rosso, C	1
Quintavalla, A	1
Lombardo, M	1
Trombini, C	1
Braga, SS	1
Borsari, C	1
Jiménez-Antón, MD	1
Eick, J	1
Bifeld, E	1
Torrado, JJ	1
Olías-Molero, AI	2
Corral, MJ	1
Santarem, N	1
Baptista, C	1
Severi, L	1
Gul, S	1
Wolf, M	1
Kuzikov, M	1
Ellinger, B	1
Reinshagen, J	1
Witt, G	1
Linciano, P	1
Tait, A	1
Costantino, L	1
Luciani, R	1
Tejera Nevado, P	1
Zander-Dinse, D	1
Franco, CH	1
Ferrari, S	1
Moraes, CB	1
Cordeiro-da-Silva, A	1
Ponterini, G	1
Clos, J	1
Alunda, JM	2
Costi, MP	1
Coimbra, ES	2
Nora de Souza, MV	1
Terror, MS	1
Pinheiro, AC	1
da Trindade Granato, J	2
Bazin, MA	1
Pagniez, F	1
Bernadat, G	1
Cavé, C	1
Ourliac-Garnier, I	1
Nourrisson, MR	1
Morgado, C	1
Picot, C	1
Leclercq, O	1
Baratte, B	1
Robert, T	1
Späth, GF	1
Rachidi, N	1
Bach, S	1
Le Pape, P	2
Marchand, P	1
Gupta, O	1
Pradhan, T	1
Bhatia, R	1
Monga, V	1
Lin, C	1
Karalic, I	1
Matheeussen, A	1
Feijens, PB	1
Hulpia, F	1
Caljon, G	2
Van Calenbergh, S	1
Ferreira, BA	1
Coser, EM	1
Saborito, C	1
Yamashiro-Kanashiro, EH	1
Lindoso, JAL	1
Coelho, AC	2
de Jong, MK	1
Rappoldt, A	1
Broere, F	1
Piek, CJ	1
Ramos, RAN	1
Giannelli, A	1
Fasquelle, F	1
Scuotto, A	1
Betbeder, D	1
Mano, C	1
Kongkaew, A	1
Tippawangkosol, P	1
Junkum, A	1
Siriyasatien, P	1
Jariyapan, N	1
Brito, JR	1
Passero, LFD	1
Bezerra-Souza, A	1
Laurenti, MD	1
Romoff, P	1
Barbosa, H	1
Ferreira, EA	1
Lago, JHG	1
Cabral, LIL	1
Pomel, S	1
Amado, PSM	1
Cristiano, MLS	1
Fontán-Matilla, E	1
Cuquerella, M	1
Tiwari, R	1
Banerjee, S	1
Tyde, D	1
Saha, KD	1
Ethirajan, A	1
Mukherjee, N	1
Chattopadhy, S	1
Pramanik, SK	1
Das, A	1
Monteiro, M	1
Prata, S	1
Cardoso, L	1
Pereira da Fonseca, I	1
Leal, RO	1
Renard, L	1
Lemaignen, A	1
Desoubeaux, G	1
Bakhos, D	1
Kumar, V	1
Yadav, S	1
Soumya, N	1
Babu, NK	1
Ortega, V	1
Giorgio, S	1
de Paula, E	1
Ponte-Sucre, A	2
Gamarro, F	2
Barrett, MP	1
López-Vélez, R	2
García-Hernández, R	1
Pountain, AW	1
Mwenechanya, R	1
Papadopoulou, B	1
Vijayakumar, S	1
Das, P	1
Fernandez-Prada, C	2
Sharma, M	1
Plourde, M	1
Bresson, E	1
Roy, G	2
Leprohon, P	3
Ouellette, M	3
Zhang, N	1
Prasad, S	1
Huyghues Despointes, CE	1
Young, J	1
Kima, PE	1
Sousa-Batista, AJ	1
Escrivani-Oliveira, D	1
Falcão, CAB	1
Philipon, CIMDS	1
Rossi-Bergmann, B	1
Calixto, SL	1
Glanzmann, N	1
Xavier Silveira, MM	1
Gorza Scopel, KK	1
Torres de Aguiar, T	1
DaMatta, RA	1
Macedo, GC	1
da Silva, AD	1
Van den Kerkhof, M	1
Van Bockstal, L	1
Gielis, JF	1
Delputte, P	1
Hendrickx, S	1
Castelo-Branco, PV	1
Alves, HJ	1
Pontes, RL	1
Maciel-Silva, VL	1
Ferreira Pereira, SR	1
Palić, S	1
Bhairosing, P	1
Beijnen, JH	2
Dorlo, TPC	1
Basmaciyan, L	1
Azas, N	1
Casanova, M	1
Berg, M	1
Mannaert, A	1
Vanaerschot, M	2
Van Der Auwera, G	1
de la Torre, BG	1
Hornillos, V	1
Luque-Ortega, JR	1
Abengózar, MA	1
Amat-Guerri, F	1
Acuña, AU	1
Rivas, L	2
Andreu, D	1
Dumetz, F	1
Roy, S	1
Arevalo, J	1
Verhaar, AP	1
Wildenberg, ME	1
Peppelenbosch, MP	1
Hommes, DW	1
van den Brink, GR	1
Fernández, OL	2
Diaz-Toro, Y	2
Ovalle, C	2
Valderrama, L	2
Muvdi, S	1
Rodríguez, I	1
Gomez, MA	2
Saravia, NG	3
Vakil, NH	1
Fujinami, N	1
Shah, PJ	1
Manna, L	1
Corso, R	1
Galiero, G	1
Cerrone, A	1
Muzj, P	1
Gravino, AE	1
Gonzalez-Fajardo, L	1
McMahon-Pratt, D	1
Badri Prasad, B	1
Shakya, A	1
Poonam, L	1
Smriti, K	1
Trinconi, CT	1
Senra, L	1
Yokoyama-Yasunaka, JK	1
Uliana, SR	1
Dohmen, LC	1
Navas, A	1
Vargas, DA	1
Gregory, DJ	1
Kip, A	1
Dorlo, TP	2
Jaiswal, S	1
Sharma, A	1
Shukla, M	1
Lal, J	1
Roberts, RM	1
Mukherjee, J	1
Phillips, D	1
Laffitte, MC	1
Légaré, D	1
Vincent, IM	1
Brotherton, MC	1
Roberts, M	1
Smith, TK	1
Ratna, A	1
Gianotti, N	1
Maillard, M	1
Gaiera, G	1
Bestetti, A	1
Cernuschi, M	1
De Bona, A	1
Lazzarin, A	1
Cinque, P	1
Bossolasco, S	1
Mateo, M	1
Maynard, L	1
Vischer, C	2
Bianciardi, P	2
Miró, G	1
Toté, K	1
Timmermans, JP	1
Brovida, C	1
Valente, M	1
Aresu, L	1
Cavicchioli, L	1
Giroud, L	1
Castagnaro, M	1
Liarte, DB	1
Murta, SM	1
Barragán, P	1
Olmo, M	1
Podzamczer, D	1
Aguiar, MG	1
Pereira, AM	1
Fernandes, AP	1
Ferreira, LA	1
Pérez-Victoria, JM	1
Bavchvarov, BI	1
Torrecillas, IR	1
Martínez-García, M	1
López-Martín, C	1
Campillo, M	1
Castanys, S	1
Machado, PR	1
Penna, G	1
Murray, HW	1
Benaim, B	1
Garcia, CR	1
Fernández, O	1
Valderrama, M	1
Castillo, H	1
Perez, M	1
Singh, N	1
Kumar, M	1
Singh, RK	1
Balasegaram, M	1
de Vries, PJ	1
Lobovská, A	1
Nohýnková, E	1
Hanson, PK	1
Malone, L	1
Birchmore, JL	1
Nichols, JW	1
Berman, J	3
Sindermann, H	5
Croft, SL	2
Engel, KR	3
Bommer, W	3
Eibl, HJ	2
Unger, C	1
Engel, J	3
Desjeux, P	1
Fischer, C	1
Sivakumar, R	1
Kuhlencord, A	1
Sundar, S	2
Zappel, H	1
Berman, JD	1
Soto, J	3
Soto, P	2
Gutteridge, WE	1
Bryceson, AD	1
Croft, S	1
Gutteridge, W	1
Karbwang, J	1
Urbina, JA	1
Seifert, K	1
Yardley, V	1
Mishra, J	1
Saxena, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705]	Phase 3	437 participants (Actual)	Interventional	2006-06-30	Completed
Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.[NCT01462500]	Phase 4	60 participants (Actual)	Interventional	2011-10-31	Completed
Evaluation of the Safety and Clinical Activity of Curaleish Lotion and Cream in the Topical Treatment of Cutaneous Leishmaniasis in Colombia[NCT04072874]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2021-01-31	Withdrawn (stopped due to Tthe study is in the approval phase by local regulatory authorities)
Randomized Clinical Trial to Evaluate the Safety and Therapeutic Response of Two ARNICA TINCTURE Treatment Regimes in the Topical Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia[NCT05094908]	Phase 1	16 participants (Anticipated)	Interventional	2023-05-03	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment

Failure

Intervention	participants (Number)
Miltefosine	85
Glucantime®	103
Thermotherapy	86

At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment

Recurrence

Intervention	participants (Number)
Miltefosine	34
Glucantime®	14
Thermotherapy	42

Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment

Article	Year
Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Amphotericin B; Antifungal Agents; Drug Repositioning; Drug Resistance, Fungal; Fluconazole; Humans;	2019
Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships. European journal of medicinal chemistry, 2021, Nov-05, Volume: 223 Topics: Animals; Cell Line, Tumor; Heterocyclic Compounds; Humans; Leishmania; Leishmaniasis; Molecular Stru	2021
Liposomal formulations in the pharmacological treatment of leishmaniasis: a review. Journal of liposome research, 2017, Volume: 27, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Compounding; Drug Delivery Systems; Drug Liberat	2017
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:12 Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Drug Therapy, Combination; Humans; Leishmania	2017
Recent progress in drug targets and inhibitors towards combating leishmaniasis. Acta tropica, 2018, Volume: 181 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Phosphorylcho	2018
Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Animals; Antiprotozoal Agents; Cytokines; Humans; Immunomodulation; Leishmania; Leishmaniasis; Phosp	2019
(Post-) Genomic approaches to tackle drug resistance in Leishmania. Parasitology, 2013, Volume: 140, Issue:12 Topics: Animals; Antiprotozoal Agents; Drug Resistance; Genome, Protozoan; Genomics; Humans; Leishmania; Lei	2013
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? Expert review of anti-infective therapy, 2014, Volume: 12, Issue:8 Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Insect Vectors; Leishmania; Leishmaniasis; P	2014
Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. Pharmacotherapy, 2015, Volume: 35, Issue:5 Topics: Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasi	2015
Miltefosine and cutaneous leishmaniasis. Current opinion in infectious diseases, 2012, Volume: 25, Issue:2 Topics: Administration, Oral; Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmaniasis; Phospho	2012
Leishmaniasis in the United States: treatment in 2012. The American journal of tropical medicine and hygiene, 2012, Volume: 86, Issue:3 Topics: Administration, Oral; Amphotericin B; Antiprotozoal Agents; Humans; Immunocompromised Host; Injectio	2012
Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. Tropical biomedicine, 2011, Volume: 28, Issue:3 Topics: Amiodarone; Antiprotozoal Agents; Calcium; Chagas Disease; Homeostasis; Humans; Leishmania; Leishman	2011
Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pacific journal of tropical medicine, 2012, Volume: 5, Issue:6 Topics: Aminoquinolines; Amphotericin B; Antigens, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agent	2012
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:11 Topics: Antiprotozoal Agents; Clinical Trials as Topic; Humans; Leishmania; Leishmaniasis; Phosphorylcholine	2012
[New drugs for treatment of parasitic infections]. Casopis lekaru ceskych, 2003, Volume: 142, Issue:3 Topics: Antiparasitic Agents; Humans; Intestinal Diseases, Parasitic; Leishmaniasis; Nitro Compounds; Phosph	2003
Current treatment approaches to leishmaniasis. Current opinion in infectious diseases, 2003, Volume: 16, Issue:5 Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Clinical Trials as Topic; Fluconazo	2003
Challenges and new discoveries in the treatment of leishmaniasis. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2004, Volume: 10, Issue:6 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania; Leishm	2004
Clinical status of agents being developed for leishmaniasis. Expert opinion on investigational drugs, 2005, Volume: 14, Issue:11 Topics: Aminoquinolines; Antiprotozoal Agents; Fluconazole; Humans; Imiquimod; Ketoconazole; Leishmaniasis;	2005
Development of miltefosine for the leishmaniases. Mini reviews in medicinal chemistry, 2006, Volume: 6, Issue:2 Topics: Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Design; HIV Infections; Humans; L	2006
Miltefosine: oral treatment of leishmaniasis. Expert review of anti-infective therapy, 2006, Volume: 4, Issue:2 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine	2006
TDR collaboration with the pharmaceutical industry. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100 Suppl 1 Topics: Antiprotozoal Agents; Drug Evaluation; Drug Industry; Female; Humans; Interprofessional Relations; L	2006
Development of miltefosine as an oral treatment for leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100 Suppl 1 Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Antineoplastic Agents; Antiprotozoal Age	2006
Miltefosine: issues to be addressed in the future. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100 Suppl 1 Topics: Abnormalities, Drug-Induced; Antiprotozoal Agents; Drug Resistance; Female; Forecasting; HIV Infecti	2006
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish	2006
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish	2006
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish	2006
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leish	2006
[Oral miltefosine to treat leishmaniasis]. Biomedica : revista del Instituto Nacional de Salud, 2006, Volume: 26 Suppl 1 Topics: Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine	2006
Chemotherapy of leishmaniasis: past, present and future. Current medicinal chemistry, 2007, Volume: 14, Issue:10 Topics: Animals; Antiprotozoal Agents; Drug Resistance; Humans; Leishmaniasis; Phosphorylcholine	2007

Article	Year
Chemotherapy of leishmaniasis Part VI: synthesis and bioevaluation of some novel terpenyl S,N- and N,N-acetals. European journal of medicinal chemistry, 2007, Volume: 42, Issue:4 Topics: Acetals; Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Leishmania donovani; Lei	2007
Chemotherapy of leishmaniasis. Part V: Synthesis and in vitro bioevaluation of novel pyridinone derivatives. European journal of medicinal chemistry, 2007, Volume: 42, Issue:5 Topics: Antiprotozoal Agents; Drug Evaluation, Preclinical; Humans; Leishmaniasis; Pyridones	2007
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies. European journal of medicinal chemistry, 2009, Volume: 44, Issue:11 Topics: Animals; Benzimidazoles; Cell Line; Cell Survival; Chagas Disease; Glucose; Leishmania braziliensis;	2009
In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12 Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Flow Cytometry; Leishmani	2009
Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents. Bioorganic & medicinal chemistry, 2010, Jan-01, Volume: 18, Issue:1 Topics: Antiprotozoal Agents; Cell Death; Cell Line; Erythrocytes; Hemolysis; Humans; Leishmania; Leishmania	2010
Synthesis and antileishmanial activity of piperoyl-amino acid conjugates. European journal of medicinal chemistry, 2010, Volume: 45, Issue:8 Topics: Alkaloids; Amino Acids; Animals; Antiprotozoal Agents; Benzodioxoles; Catalytic Domain; Cricetinae;	2010
Potent antiprotozoal activity of a novel semi-synthetic berberine derivative. Bioorganic & medicinal chemistry letters, 2011, May-01, Volume: 21, Issue:9 Topics: Animals; Antiprotozoal Agents; Berberine; Chlorocebus aethiops; Disease Models, Animal; Inhibitory C	2011
Chemotherapy of leishmaniasis. Part IX: synthesis and bioevaluation of aryl substituted ketene dithioacetals as antileishmanial agents. Bioorganic & medicinal chemistry letters, 2012, Nov-01, Volume: 22, Issue:21 Topics: Acetals; Animals; Antiprotozoal Agents; Cricetinae; Ethylenes; Ketones; Leishmania donovani; Leishma	2012
Chemotherapy of leishmaniasis part X: synthesis and bioevaluation of novel terpenyl heterocycles. Bioorganic & medicinal chemistry letters, 2013, Jan-01, Volume: 23, Issue:1 Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Cell Survival; Chalcones; Cricetinae; Disease Model	2013
Triazolopyridyl ketones as a novel class of antileishmanial agents. DNA binding and BSA interaction. Bioorganic & medicinal chemistry, 2014, Aug-01, Volume: 22, Issue:15 Topics: Animals; Antiprotozoal Agents; Binding, Competitive; Cattle; Cell Line; Cell Survival; Disease Model	2014
Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents. Bioorganic & medicinal chemistry letters, 2015, Jan-15, Volume: 25, Issue:2 Topics: Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cell Survival; Cells, Cultured; Chlorocebu	2015
New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents. European journal of medicinal chemistry, 2015, Apr-13, Volume: 94 Topics: Animals; Antimalarials; Chemistry Techniques, Synthetic; Chloroquine; Drug Design; Drug Evaluation,	2015
Synthesis of 5-isoxazol-3-yl-pyrimidine nucleosides as potential antileishmanial agents. Bioorganic & medicinal chemistry letters, 2015, Jul-01, Volume: 25, Issue:13 Topics: Animals; Antiprotozoal Agents; Drug Design; Humans; Isoxazoles; Leishmania donovani; Leishmaniasis;	2015
Aminothiazoles: Hit to lead development to identify antileishmanial agents. European journal of medicinal chemistry, 2015, Sep-18, Volume: 102 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Dose-Response Relatio	2015
Anti-leishmanial and cytotoxic activities of amino acid-triazole hybrids: Synthesis, biological evaluation, molecular docking and in silico physico-chemical properties. Bioorganic & medicinal chemistry letters, 2017, 05-01, Volume: 27, Issue:9 Topics: Amino Acids; Antiprotozoal Agents; Click Chemistry; Humans; Leishmania donovani; Leishmaniasis; Mole	2017
Evaluation of synthetic substituted 1,2-dioxanes as novel agents against human leishmaniasis. European journal of medicinal chemistry, 2019, May-15, Volume: 170 Topics: Animals; Chlorocebus aethiops; Dioxanes; Drug Design; Humans; Leishmania; Leishmaniasis; Parasitic S	2019
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Animals; Antiprotozoal Agents; Cricetinae; Drug Evaluation, Preclinical; Drug Resistance; Flavonols;	2019
Synthesis, biological activity, and mechanism of action of new 2-pyrimidinyl hydrazone and N-acylhydrazone derivatives, a potent and new classes of antileishmanial agents. European journal of medicinal chemistry, 2019, Dec-15, Volume: 184 Topics: Animals; Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Discovery; Hydrazones; Leishma	2019
In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition. European journal of medicinal chemistry, 2021, Jan-15, Volume: 210 Topics: Casein Kinase I; Humans; Imidazoles; Leishmania major; Leishmaniasis; Models, Molecular; Protein Kin	2021
Exploration of 6-methyl-7-(Hetero)Aryl-7-Deazapurine ribonucleosides as antileishmanial agents. European journal of medicinal chemistry, 2022, Jul-05, Volume: 237 Topics: Animals; Antiprotozoal Agents; Cricetinae; Leishmania; Leishmaniasis; Mice; Nucleosides; Purine Nucl	2022
In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis. Experimental parasitology, 2023, Volume: 246 Topics: Amphotericin B; Antiprotozoal Agents; Brazil; Humans; Leishmania; Leishmaniasis; Leishmaniasis, Cuta	2023
Survival time and prognostic factors in canine leishmaniosis in a non-endemic country treated with a two-phase protocol including initial allopurinol monotherapy. Parasites & vectors, 2023, May-15, Volume: 16, Issue:1 Topics: Allopurinol; Animals; Creatinine; Dog Diseases; Dogs; Humans; Leishmania infantum; Leishmaniasis; Le	2023
Effective immuno-therapeutic treatment of Canine Leishmaniasis. PLoS neglected tropical diseases, 2023, Volume: 17, Issue:5 Topics: Animals; Dog Diseases; Dogs; Leishmania infantum; Leishmaniasis; Leishmaniasis, Visceral	2023
In vitro susceptibility to miltefosine of amphotericin B-resistant Leishmania (Mundinia) martiniquensis. Parasitology research, 2023, Volume: 122, Issue:12 Topics: Amphotericin B; Antiprotozoal Agents; Chronic Disease; Humans; Leishmania; Leishmaniasis; Leishmania	2023
Antileishmanial activity and ultrastructural changes of related tetrahydrofuran dineolignans isolated from Saururus cernuus L. (Saururaceae). The Journal of pharmacy and pharmacology, 2019, Volume: 71, Issue:12 Topics: Animals; Antiprotozoal Agents; Furans; Leishmania; Leishmaniasis; Lignans; Mice; Mice, Inbred BALB C	2019
Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against Molecules (Basel, Switzerland), 2020, Jan-22, Volume: 25, Issue:3 Topics: Animals; Antiprotozoal Agents; Leishmania donovani; Leishmaniasis; Mice; Phosphorylcholine; Tetraoxa	2020
Scientometric analysis of chemotherapy of canine leishmaniasis (2000-2020). Parasites & vectors, 2021, Jan-09, Volume: 14, Issue:1 Topics: Allopurinol; Amphotericin B; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Combinations; D	2021
Redox-Responsive Nanocapsules for the Spatiotemporal Release of Miltefosine in Lysosome: Protection against Bioconjugate chemistry, 2021, 02-17, Volume: 32, Issue:2 Topics: Animals; Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis; Lysosomes; Mice; Nanocaps	2021
Diagnosis and clinical management of canine leishmaniosis by general veterinary practitioners: a questionnaire-based survey in Portugal. Parasites & vectors, 2021, Jun-07, Volume: 14, Issue:1 Topics: Adult; Allopurinol; Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Humans; Knowledge; Le	2021
Case Report: Progressive Dysphonia and Dysphagia due to Laryngeal Leishmaniasis. The American journal of tropical medicine and hygiene, 2021, 06-14, Volume: 105, Issue:2 Topics: Aged; Amphotericin B; Antiprotozoal Agents; Deglutition Disorders; Diagnosis, Differential; Dysphoni	2021
Biochemical and inhibition studies of glutamine synthetase from Leishmania donovani. Microbial pathogenesis, 2017, Volume: 107 Topics: Antibodies, Protozoan; Base Sequence; DNA, Protozoan; Enzyme Activation; Enzyme Inhibitors; Escheric	2017
High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms. International journal for parasitology. Drugs and drug resistance, 2018, Volume: 8, Issue:2 Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Cosmids; CRISPR-Cas Systems; Drug Resistanc	2018
Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections. Cellular microbiology, 2018, Volume: 20, Issue:11 Topics: Animals; Antiprotozoal Agents; Gene Knockdown Techniques; Green Fluorescent Proteins; Intracellular	2018
Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:10 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chalcones; Female; Leishmania; Leishmania infan	2018
Novel organic salts based on quinoline derivatives: The in vitro activity trigger apoptosis inhibiting autophagy in Leishmania spp. Chemico-biological interactions, 2018, Sep-25, Volume: 293 Topics: Animals; Antiprotozoal Agents; Apoptosis; Autophagy; Female; Leishmania; Leishmaniasis; Macrophages;	2018
Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility. Parasitology research, 2018, Volume: 117, Issue:11 Topics: Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Cells, Cultured; Drug Resistance; Female; I	2018
Ascorbic acid reduces the genetic damage caused by miltefosine (hexadecylphosphocholine) in animals infected by Leishmania (Leishamnia) infantum without decreasing its antileishmanial activity. International journal for parasitology. Drugs and drug resistance, 2019, Volume: 9 Topics: Animals; Antiprotozoal Agents; Ascorbic Acid; DNA Damage; Injections, Intraperitoneal; Leishmania in	2019
A potential acetyltransferase involved in Leishmania major metacaspase-dependent cell death. Parasites & vectors, 2019, May-27, Volume: 12, Issue:1 Topics: Acetyltransferases; Apoptosis; Caspases; Curcumin; Leishmania major; Leishmaniasis; Phosphorylcholin	2019
A BODIPY-embedding miltefosine analog linked to cell-penetrating Tat(48-60) peptide favors intracellular delivery and visualization of the antiparasitic drug. Amino acids, 2014, Volume: 46, Issue:4 Topics: Anthelmintics; Boron Compounds; Cell Line; Cell-Penetrating Peptides; Drug Design; Humans; Leishmani	2014
Repurposing miltefosine for the treatment of immune-mediated disease? The Journal of pharmacology and experimental therapeutics, 2014, Volume: 350, Issue:2 Topics: Adaptive Immunity; Adjuvants, Immunologic; Drug Discovery; Humans; Immune System Diseases; Immunity,	2014
Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia. PLoS neglected tropical diseases, 2014, Volume: 8, Issue:5 Topics: Adolescent; Adult; Aged; Antimony; Child; Child, Preschool; Cohort Studies; Colombia; Drug Resistanc	2014
Miltefosine (Impavido) for leishmaniasis. The Medical letter on drugs and therapeutics, 2014, Sep-15, Volume: 56, Issue:1451 Topics: Antiprotozoal Agents; Drug Approval; Humans; Leishmaniasis; Phosphorylcholine; United States; United	2014
Ex vivo host and parasite response to antileishmanial drugs and immunomodulators. PLoS neglected tropical diseases, 2015, Volume: 9, Issue:5 Topics: Adolescent; Animals; Antiprotozoal Agents; Female; Humans; Immunologic Factors; Interferon-alpha; In	2015
Caruncular Leishmaniasis--An Unusual Case. Orbit (Amsterdam, Netherlands), 2015, Volume: 34, Issue:4 Topics: Antiprotozoal Agents; Diagnosis, Differential; Eye Diseases; Humans; Leishmaniasis; Male; Middle Age	2015
Leishmania is not prone to develop resistance to tamoxifen. International journal for parasitology. Drugs and drug resistance, 2015, Volume: 5, Issue:3 Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance;	2015
Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS. The Journal of biological chemistry, 2016, Apr-29, Volume: 291, Issue:18 Topics: ATP-Binding Cassette Transporters; Biological Transport, Active; Cell Line, Tumor; Gene Knockdown Te	2016
LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma. Bioanalysis, 2016, Volume: 8, Issue:6 Topics: Administration, Oral; Adult; Animals; Antiprotozoal Agents; Chromatography, High Pressure Liquid; Cr	2016
Laryngeal leishmaniasis in a patient taking inhaled corticosteroids. BMJ case reports, 2016, Jun-21, Volume: 2016 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Antiemetics; Antiprotozoal Agents; Asthma	2016
Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance. Parasitology research, 2016, Volume: 115, Issue:10 Topics: Alleles; Animals; Antiprotozoal Agents; High-Throughput Nucleotide Sequencing; Humans; Leishmania in	2016
Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms. PLoS neglected tropical diseases, 2016, Volume: 10, Issue:12 Topics: Amphotericin B; Antiprotozoal Agents; Drug Resistance; Humans; Leishmania infantum; Leishmaniasis; M	2016
Leishmania recombinant antigen modulates macrophage effector function facilitating early clearance of intracellular parasites. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, Volume: 110, Issue:10 Topics: Animals; Antigens, Protozoan; Cricetinae; Disease Models, Animal; Leishmania; Leishmaniasis; Macroph	2016
Development of new antileishmanial drugs--current knowledge and future prospects. Journal of enzyme inhibition and medicinal chemistry, 2008, Volume: 23, Issue:5 Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania; Leishmaniasis; Phospho	2008
Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients. The new microbiologica, 2008, Volume: 31, Issue:3 Topics: Adult; Amphotericin B; Anti-Retroviral Agents; Antiprotozoal Agents; CD4 Lymphocyte Count; HIV Infec	2008
Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitology research, 2009, Volume: 105, Issue:1 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Bone Marrow; Dog Diseases; Dogs; Female; Inject	2009
In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Antiprotozoal Agents; Cells, Cultured; Inhibitor	2009
Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. Toxicologic pathology, 2009, Volume: 37, Issue:6 Topics: Animals; Antiprotozoal Agents; Body Weight; Dogs; Female; Fluorescent Antibody Technique; Histocytoc	2009
Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species. Parasitology research, 2010, Volume: 107, Issue:1 Topics: Amphotericin B; Animals; Antimony Potassium Tartrate; Antiprotozoal Agents; Culture Media; Drug Resi	2010
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:1 Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmanias	2010
Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Administration, Oral; Administration, Topical; Animals; Anti-Bacterial Agents; Antiprotozoal Agents;	2010
Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:8 Topics: Aminoquinolines; Antimony; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Drug Resistance,	2011
Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. Journal of clinical microbiology, 2012, Volume: 50, Issue:7 Topics: Antiprotozoal Agents; Cell Line; Humans; Leishmania; Leishmaniasis; Macrophages; Meglumine; Meglumin	2012
New treatment for leishmaniasis is 95% effective. Bulletin of the World Health Organization, 2002, Volume: 80, Issue:8 Topics: Antiprotozoal Agents; Developing Countries; Humans; India; Leishmaniasis; Phosphorylcholine; Treatme	2002
Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. The Journal of biological chemistry, 2003, Sep-19, Volume: 278, Issue:38 Topics: Alleles; Antiprotozoal Agents; Biological Transport; Cell Division; Cell Membrane; Cycloheximide; Do	2003
Miltefosine (Impavido): the first oral treatment against leishmaniasis. Medical microbiology and immunology, 2004, Volume: 193, Issue:4 Topics: Administration, Oral; Animals; Antiprotozoal Agents; Humans; Leishmaniasis; Phosphorylcholine	2004
Leishmaniasis. Nature reviews. Microbiology, 2004, Volume: 2, Issue:9 Topics: Animals; Antiprotozoal Agents; Humans; Insect Control; Leishmania; Leishmaniasis; Paromomycin; Phosp	2004
Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Nov-15, Volume: 39, Issue:10 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Female; HIV Infections; Humans; Immunocompromised	2004
[Leishmaniasis--oral treatment with hexadecylphosphocholine]. Wiener klinische Wochenschrift, 2004, Volume: 116 Suppl 4 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Child; Clinical Trials as Topic; Drug Resistance;	2004

miltefosine and Leishmania Infection